Abstract OBJECTIVE: Cysteinyl leukotriene (CysLTs) plays an important role in airway inflammation and remodeling in asthma. Measurement of urinary leukotriene E4 (LTE4) is a sensitive and noninvasive method of assaying total body CysLTs level. This study aimed to evaluate the clinical significance of urinary leukotriene E4 (LTE4) in childhood asthma. METHODS: Sixty children with acute asthma were randomly divided into montelukast (leukotriene receptor antagonist) treatment and conventional treatment groups (n=30 each). Urinary LTE4 levels were measured using ELISA and the airway resistance Rint was assessed by the lung function instrument at the acute and the convalescence phases. Twenty healthy children were used as the control group. RESULTS: Urinary LTE4 levels in asthmatic children at the acute and the convalescence phases were significantly higher than those in the control group (P<0.01). The urinary LTE4 levels at the convalescence phase were significantly reduced compared with those at the acute phase in asthmatic children (P<0.01). More significantly decreased urinary LTE4 levels were noted in the montelukast treatment group than the conventional treatment group at the convalescence phase (P<0.01). In the acute phase, there was no correlation between urinary LTE4 level and Rint in asthmatic children. CONCLUSIONS: Urinary LTE4 level is significantly increased in children with acute asthma. Urinary LTE4 is a useful marker for the diagnosis of asthma and can be as a predictor of asthma control and marker of susceptibility to treatment with leukotriene receptor antagonists.[Chin J Contemp Pediatr, 2009, 11 (11):909-912]
[5]Mita H, Turikisawa N, Yamada T, Taniguchi M. Quantification of leukotriene B4 glucuronide in human urine[J]. Prostaglandins Other Lipid Mediators, 2007, 83(1):42-49.
[6]Smith CM, Hawksworth RJ, Thien FC. Urinary leukotriene E4 in bronchial asthma[J]. Eur Respir J, 1992, 5(6):693-699.
[8]Knorr B, Franehi LM, Bissard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast,a leukotriene receptor antagonist,for the treatment of persistent asthma in children aged 2 to 5 years[J]. Pediatrics, 2005, 108(5):E48.
[9]Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P.A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma[J].Pulm Pharmacol Therap, 2007, 20(6):691-700.
[10]Kleinman R, Mura M, Liu MY. 半胱氨酰白三烯拮抗剂治疗儿童哮喘[J].中国当代儿科杂志,2005,7(5):398-403.